The SPARC score: A multifactorial outcome prediction model for patients undergoing radical cystectomy for bladder cancer

Journal of Urology

Volumn 190, Issue 6, 2013, Pages 2005-2010

  Eisenberg, Manuel S ^a   Boorjian, Stephen A ^a   Cheville, John C ^a   Thompson, R Houston ^a   Thapa, Prabin ^a   Kaushik, Dharam ^a   Frank, Igor ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cystectomy; Mortality; Nomograms; Prognosis; Urinary bladder neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; CYSTECTOMY; DISTANT METASTASIS; FEMALE; HUMAN; HYDRONEPHROSIS; KAPLAN MEIER METHOD; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT COUNSELING; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; SURVIVAL PREDICTION AFTER RADICAL CYSTECTOMY SCORE; TRANSITIONAL CELL CARCINOMA;

EID: 84888636623     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.06.022     Document Type: Article

References (29)

1. American Cancer Society: Cancer Facts and Figures 2012. Atlanta: American Cancer Society 2012.
2. Lopez-Beltran A: Bladder cancer: clinical and pathological profile. Scand J Urol Nephrol Suppl 2008;218:95.
3. Stein JP, Lieskovsky G, Cote R et al: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. J Clin Oncol 2001;19:666.
4. Shariat SF, Karakiewicz PI, Palapattu GS et al: Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 2006;12:6663.
5. Karakiewicz PI, Shariat SF, Palapattu GS et al: Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 2006;176:1354.
6. Bochner BH, Kattan MW and Vora KC: Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006;24:3967.
7. Fairey AS, Jacobsen NE, Chetner MP et al: Associations between comorbidity, and overall survival and bladder cancer specific survival after radical cystectomy: results from the Alberta Urology Institute Radical Cystectomy database. J Urol 2009;182:85.
8. Boorjian SA, Kim SP, Tollefson MK et al: Comparative performance of comorbidity indices for estimating perioperative and 5-year allcause mortality following radical cystectomy for bladder cancer. J Urol 2013;190:55.
9. Mayr R, May M, Martini T et al: Comorbidity and performance indices as predictors of cancerindependent mortality but not of cancerspecific mortality after radical cystectomy for urothelial carcinoma of the bladder. Eur Urol 2012;62:662.
10. Bartsch GC, Kuefer R, Gschwend JE et al: Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series. Eur Urol 2007;51:690.
11. Rink M, Zabor EC, Furberg H et al: Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. Eur Urol 2013;64:456.
12. Yafi FA, Aprikian AG, Chin JL et al: Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int 2011;108:539.
13. Lund L, Jacobsen J, Clark P et al: Impact of comorbidity on survival of invasive bladder cancer patients, 1996-2007: a Danish populationbased cohort study. Urology 2010;75:393.
14. Koppie TM, Serio AM, Vickers AJ et al: Ageadjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer 2008;112:2384.
15. Lee CT, Madii R, Daignault S et al: Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol 2006;175:1262.
16. Harrell FE Jr, Lee KL and Mark DB: Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361.
17. Fine J and Gray R: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496.
18. Todenhofer T, Renninger M, Schwentner C et al: A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors. BJU Int 2012;110:E533.
19. Sonpavde G, Khan MM, Svatek RS et al: Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. BJU Int 2011;108:687.
20. Sonpavde G, Khan MM, Svatek RS et al: Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol 2011;185:1216.
21. Xylinas E, Cha EK, Sun M et al: Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. Br J Cancer 2012;107:1826.
22. Abdollah F, Sun M, Schmitges J et al: Development and validation of a reference table for prediction of postoperative mortality rate in patients treated with radical cystectomy: a population-based study. Ann Surg Oncol 2012;19:309.
23. Morgan TM, Keegan KA, Barocas DA et al: Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. J Urol 2011;186:829.
24. Mitra AP, Skinner EC, Miranda G et al: A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer. BJU Int 2013;111:240.
25. Moller AM, Villebro N, Pedersen T et al: Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. Lancet 2002;359:114.
26. Riester M, Taylor JM, Feifer A et al: Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res 2012;18:1323.
27. Shariat SF, Chromecki TF, Cha EK et al: Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. J Urol 2012;187:457.
28. Wei H, Kamat AM, Aldousari S et al: Genetic variations in the transforming growth factor beta pathway as predictors of bladder cancer risk. PLoS One 2012;7:e51758.
29. Catto JW, Abbod MF, Linkens DA et al: Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. Clin Cancer Res 2009;15:3150.